CU01
Phase 2An oral candidate for diabetic nephropathy; in a 240-patient Phase 2b at 24 Korean university hospitals, the primary endpoint (uACR) improved 21–22% versus placebo.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has reported Phase 2b results for its kidney-disease candidate and licensed a retinal bispecific antibody abroad.
Roles often seen at this stageClinical & PV · BD & licensing · Research & development
Develops drug candidates for hard-to-treat vascular-related kidney and retinal diseases.
An oral candidate for diabetic nephropathy; in a 240-patient Phase 2b at 24 Korean university hospitals, the primary endpoint (uACR) improved 21–22% versus placebo.
A Tie2-activating/VEGF-blocking bispecific antibody co-developed with Mabtics, licensed in May 2026 to Memento Medicines (US) for up to USD 1.07775 billion.
An oral candidate for retinal disease.
Licensed the retinal bispecific antibody MT-103 to Memento Medicines in the US.
Reported topline results of the CU01 Phase 2b trial in diabetic nephropathy.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.